CIViC Evidence Items

23 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	RET	C609Y	Predisposing	Supports	Predisposition	Medullary Thyroid Carcinoma		Calva et al., 2009
C	RET	M918T AND RET V804M	Predictive	Supports	Sensitivity/Response	Medullary Thyroid Carcinoma	Selpercatinib	Subbiah et al., 2018
B	RET	M918T	Predictive	Supports	Sensitivity/Response	Medullary Thyroid Carcinoma	Cabozantinib	Sherman et al., 2016
A	RET	Mutation	Predictive	Supports	Sensitivity/Response	Medullary Thyroid Carcinoma	Selpercatinib	Wirth et al., 2020
D	RET	M918T	Oncogenic	Supports	Oncogenicity	Cancer		Zhao et al., 2020
A	RET	Mutation	Predictive	Supports	Sensitivity/Response	Medullary Thyroid Carcinoma	Selpercatinib	Hadoux et al., 2023
B	RET	Mutation	Prognostic	Supports	Poor Outcome	Medullary Thyroid Carcinoma		Elisei et al., 2008
D	RET	C634W	Predictive	Supports	Resistance	Medullary Thyroid Carcinoma	Motesanib	Coxon et al., 2012
D	RET	M918T	Predictive	Supports	Resistance	Medullary Thyroid Carcinoma	Motesanib	Coxon et al., 2012
D	RET	M918T	Predictive	Supports	Sensitivity/Response	Medullary Thyroid Carcinoma	JAK2 Inhibitor AZD1480	Couto et al., 2012
B	RET	M918T	Predictive	Supports	Sensitivity/Response	Medullary Thyroid Carcinoma	Sorafenib	Lam et al., 2010
C	RET	Overexpression	Predictive	Supports	Sensitivity/Response	Papillary Adenocarcinoma	Sunitinib	Jones et al., 2010
B	RET	Overexpression	Prognostic	Supports	Poor Outcome	Lung Adenocarcinoma		Kosari et al., 2014
C	RET	V804M	Predictive	Supports	Sensitivity/Response	Medullary Thyroid Carcinoma	Selpercatinib	Alexander E. Drilon, 2018, ASCO Annual Meeting, Abstract 102
B	RET	Mutation	Predictive	Supports	Sensitivity/Response	Medullary Thyroid Carcinoma	Selpercatinib	Alexander E. Drilon, 2018, ASCO Annual Meeting, Abstract 102
C	RET	M918T AND RET G810S	Predictive	Supports	Resistance	Medullary Thyroid Carcinoma	Selpercatinib	Solomon et al., 2020
D	RET	E632_L633del	Oncogenic	Supports	Oncogenicity	Cancer		Ceccherini et al., 1997
D	RET	C634R	Oncogenic	Supports	Oncogenicity	Cancer		Ceccherini et al., 1997
D	RET	M918T	Oncogenic	Supports	Oncogenicity	Cancer		Ceccherini et al., 1997
B	RET	M918T	Oncogenic	Supports	Oncogenicity	Medullary Thyroid Carcinoma		Elisei et al., 2008
B	RET	M918T	Prognostic	Supports	Poor Outcome	Medullary Thyroid Carcinoma		Egawa et al., 1998
D	RET	Overexpression	Predictive	Supports	Sensitivity/Response	Breast Cancer	Vandetanib	Hatem et al., 2016
C	RET	M918T	Predisposing	Supports	Predisposition	Medullary Thyroid Carcinoma		Romei et al., 2018